Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06069570 · ClinicalTrials.gov registry record · Phase 1
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
A Phase 1 study of Carcinoma, Non-Small-Cell Lung Cancer and Bone Metastases From Solid Tumors, sponsored by Kiromic BioPharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 5
- Study locations
NCT06069570: Recruiting Phase 1 study of Carcinoma, Non-Small-Cell Lung Cancer and Bone Metastases From Solid Tumors, sponsored by Kiromic BioPharma.
NCT06069570 is a Phase 1 study of Carcinoma, Non-Small-Cell Lung Cancer and Bone Metastases From Solid Tumors that is actively recruiting participants, run by Kiromic BioPharma. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06069570, a Phase 1 study of Carcinoma, Non-Small-Cell Lung Cancer and Bone Metastases From Solid Tumors, is actively recruiting participants, sponsored by Kiromic BioPharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.
Primary Outcome
DLT, defined as the occurrence or start of a clinically significant Grade 3 or greater AE (per CTCAE v5.0) occurring during the DLT assessment period that cannot be attributed to disease progression, intercurrent illness, or concomitant medication.
Conditions Studied
Interventions
- BIOLOGICAL KB-GDT-01
Study Locations (5)
Arizona
- The University of Arizona Cancer Center - Tucson
California
- Beverly Hills Cancer Center - Beverly Hills
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Texas
- Texas Oncology - Tyler - Tyler
Virginia
- Virginia Oncology Associates - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
What NCT06069570 shows while recruiting
NCT06069570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 2 conditions, with Carcinoma, Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which KB-GDT-01 is the first listed.
NCT06069570 lists 5 locations in 5 states (Arizona, California, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT06069570 about?
NCT06069570 is a clinical study titled "Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases". This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunot...
What is the current status of trial NCT06069570?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-11-07. Estimated completion is 2026-10.
What conditions does trial NCT06069570 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors.
What interventions are being tested in trial NCT06069570?
The interventions under investigation include: KB-GDT-01 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06069570?
This trial is sponsored by Kiromic BioPharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06069570 being conducted?
This trial has 5 study locations across Arizona, California, Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06069570's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI